Lilly ECO 2026 Preview: Orforglipron Post-Hoc Subgroup Analysis in Adults Aged 65+ Drawn from ATTAIN-1 + ATTAIN-2 Phase 3 Pool
A post-hoc subgroup analysis of Eli Lilly's orforglipron (Foundayo) in adults aged 65 and older, drawn from the ATTAIN-1 and ATTAIN-2 Phase 3 programs, will be presented at ECO 2026 in Istanbul May 12-15. The analysis pools 616 randomized participants (613 treated) — 118 on 6 mg, 135 on 12 mg, 146 on 36 mg orforglipron, and 214 placebo — across patients with and without type 2 diabetes. The geriatric data set addresses a long-standing clinical gap: incretin trials have systematically underenrolled adults over 65, the population most affected by obesity-related comorbidities and the most likely to face polypharmacy-related GI tolerability concerns. Lead author Dr. Deborah Horn (UTHealth Houston McGovern Medical School). The presentation is among the ECO 2026 abstracts that will shape geriatric prescribing patterns for the first FDA-approved GLP-1 pill that does not require fasting or water restrictions.